Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?

Executive Summary

Agency has scheduled only two advisory committee meetings in 2017; does it indicate the agency plans to conduct fewer meetings going forward?

You may also be interested in...



FDA's Savings Machine: The White Oak Conference Room

The Great Room, now the home of most US FDA workshops and advisory committee meetings, has created significant savings for the agency, GAO says.

US FDA May Change Advisory Committee Planning, Member Screening

Departing Commissioner says that special government employee procedure especially is in need of reform.

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says

US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel